Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

SAN DIEGO, March 6, 2023 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2022. Key…

Leave a Reply

Your email address will not be published. Required fields are marked *